Disease detection, access to care and remote patient monitoring are just a few areas in which AI is expected to aid rheumatology, but there will still be room for the human touch.
Search results for: pediatric rheumatology
FDA Approval Sought for 2 Pediatric Indications for Guselkumab
The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
mRNA CAR T Cell Therapy Receives FDA’s Rare Pediatric Designation to Treat Juvenile Dermatomyositis
FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Small Postcard, Big Impact: ACR’s New Grassroots Group Empowers Members to Be Rheumatology Advocates
Helping ACR/ARP members talk to lawmakers about rheumatology-related policy is a key part of the ACR’s advocacy efforts. A postcard-writing campaign to Congress highlights outreach efforts of a new member engagement working group.
2024 Rheumatology Fellowship Match Day Results
Match Day Results Highlight Continued Interest in Adult Rheumatology & Sharp Declines in Pediatric Rheumatology The ACR applauds another successful recruitment season for rheumatology and welcomes an impressive pool of applicants to the specialty. Ninety-nine percent of adult rheumatology positions were filled for the 2024 appointment year as part of the National Resident Matching Program…
FDA Officials Discuss Extrapolation & Confusion Around Pediatric Therapies
A session at ACR Convergence 2024 addressed several recent drug approvals in pediatric rheumatology and a safety update for IL-1/IL-6 inhibitors.
Toward Personalized Medicine in Pediatric Lupus
At this ACR Convergence 2024 session, discussion centered on novel techniques that offer hope for developing personalized therapies for pediatric SLE.
New ACR President Carol Langford, MD, MHS, Has Optimistic Outlook for Future of Rheumatology
“At my very first annual meeting of the ACR, I saw how the ACR brought the whole rheumatology community together, and I knew right away that it was an organization that I wanted to be a part of,” Dr. Langford says. In late November, she became the 88th president of the ACR and looks forward to continuing its focus on education, research and building community.
The Great Pediatric Debate 2024: Cessation or Continuation of Biologics in sJIA Lung Disease?
Washington D.C.—At a Sunday, Nov. 17, Pediatrics Great Debate session of ACR Convergence, speakers argued whether patients with systemic juvenile idiopathic arthritis (sJIA) should continue their interleukin (IL) 1/IL-6 biologics if lung disease is suspected. Randy Q. Cron, MD, PhD, the director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham,…
The Who, What & Where of Rheumatology
In the Medical Education Year in Review session at ACR Convergence 2024, David Leverenz, MD, MEd, discussed the current make-up of rheumatology, how competency is measured and how to help rheumatology fellows thrive.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 95
- Next Page »